|
Orthologous residues
|
|
FOXO4 (human): S262‑p, FOXO4 (mouse): S262‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], BHK-21 (fibroblast), HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
pharmacological activator of upstream enzyme, phospho-antibody
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
leptomycin B
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
transcription, altered
|